Fatty Acid Synthase (FASN)
Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.
Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.
All Product Categories
-
Fatty Acid Synthase (FASN) Inhibitors
(96)
View all products
-
Fatty Acid Synthase (FASN) Activators
(3)
View all products
-
Fatty Acid Synthase (FASN) Modulators
(2)
View all products
-
Fatty Acid Synthase (FASN) Chemicals
(4)
View all products
-
Fatty Acid Synthase (FASN) Control
(1)
View all products
-
Fatty Acid Synthase (FASN) Ligand
(1)
View all products
-
Fatty Acid Synthase (FASN) Related Products (115)
Related Products (115)
-
Antibodies (9)
-
SREBP/SCAP-IN-1
0 ImagesCat. No.: HY-149657CAS No.: 2763493-89-4SREBP/SCAP-IN-1(compound 10b) is a selectiveSREBP/SCAPinhibitor.
-
FT113 (Standard)
0 ImagesCat. No.: HY-111551RCAS No.: 1630808-89-7FT113 (Standard) is the analytical standard of FT113 (HY-111551). This product is intended for research and analytical applications. FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC50 of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC50, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo.
-
HadAB/InhA=IN-1
0 ImagesCat. No.: HY-187335HadAB/InhA=IN-1 is a dual inhibitor of Mycobacterium tuberculosis InhA and HadAB with an InhA IC50 of 0.81 μM. HadAB/InhA=IN-1 inhibits InhA enzymatic activity in the FAS-II pathway of mycolic acid biosynthesis. HadAB/InhA=IN-1 undergoes EthA-mediated activation to covalently bind HadA and inhibit HadAB dehydratase function in the same FAS-II pathway. HadAB/InhA=IN-1 reduces mycolic acid-containing lipid and mycolic acid production, and accumulates standard fatty acids in Mycobacterium tuberculosis. HadAB/InhA=IN-1 exhibits antimycobacterial activity against drug-susceptible, ethA-deficient, and multi-drug-resistant Mycobacterium tuberculosis isolates. HadAB/InhA=IN-1 shows cytotoxic effects against human cancer and immortalized normal lung fibroblast cells. HadAB/InhA=IN-1 can be used for the research of tuberculosis.
-
Borapetoside E
0 ImagesCat. No.: HY-N2953CAS No.: 151200-49-6Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue.
-
Yamogenin (Standard)
0 ImagesYamogenin (Standard) is the analytical standard of Yamogenin. This product is intended for research and analytical applications. Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC50 of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer.
-
NPD6433
0 ImagesCat. No.: HY-167879ANPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis.
-
SREBP/SCAP-IN-2
0 ImagesCat. No.: HY-149658CAS No.: 2763493-94-1SREBP/SCAP-IN-2(compound 13) is a selectiveSREBP/SCAPinhibitor.
-
trans-Chalcone (Standard)
0 Imagestrans-Chalcone (Standard) is the analytical standard of trans-Chalcone (HY-Y0598). This product is intended for research and analytical applications. trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and α-amylase inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity.
-
Idalaptican pegol
0 ImagesCat. No.: HY-185926CAS No.: 2364414-05-9Synonyms: NOX-D21; AON-D21Ldalaptican pegol (AON-D21; NOX-D21) is a PEGylated mixed RNA/DNA L-aptamer that specifically binds to complement C5a. Ldalaptican pegol binds to C5a and the C5a moiety on uncleaved C5, thereby blocking C5a signaling. This inhibition suppresses downstream inflammatory responses, immune cell infiltration and chemotaxis, the release of pro-fibrotic factors, and abnormalities in lipid metabolism signaling pathways. Ldalaptican pegol can also alleviate allograft rejection. Ldalaptican pegol can be used in research on inflammatory muscle diseases, Duchenne muscular dystrophy (DMD), diabetes, renal fibrosis, and allograft organ transplant rejection.
-
Maltitol (Standard)
0 ImagesMaltitol (Standard) is the analytical standard of Maltitol (HY-B2122). This product is intended for research and analytical applications. Maltitol is an orally active polyol and sugar alcohol sweetener produced by the hydrogenation of maltose. Maltitol can replace sucrose and has characteristics of having a minor impact on blood sugar and potential prebiotic effects.
-
Pedunculoside (Standard)
0 ImagesCat. No.: HY-N0458RCAS No.: 42719-32-4Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation.
-
Rebaudioside A (Standard)
0 ImagesCat. No.: HY-N0466RCAS No.: 58543-16-1Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
